Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

ABSTRACT: The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.

DISEASE(S): Metastatic Colorectal Cancer,Cáncer Colorrectal Metastásico Con Ras Mutado O No Mutado,Mutant Ras Or Wild-type (wt) Ras Metastatic Colorectal Cancer,Colorectal Neoplasms Malignant,Colorectal Cancer Recurrent,Colorectal Neoplasms,Colorectal Cancer Metastatic

PROVIDER: 2150444 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR